Stock Price of Mast Therapeutics, Inc. (MSTX) Increases 10.08%

Mast Therapeutics, Inc.s in-depth stock price analysis indicates that the stock price has rallied 99.18% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -62.46% . Looking at the past 52 week period, the stock price is down -42.72% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Mast Therapeutics, Inc. has a negative value of -68.18 compared to overall market performance. Mast Therapeutics, Inc. (NYSEMKT:MSTX) has climbed 10.08% in the past week and advanced 6.78% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 9.19% and the outperformance has advanced to 4.87% for the last 4 weeks period.

Mast Therapeutics, Inc. (NYSEMKT:MSTX) : On Friday heightened volatility was witnessed in Mast Therapeutics, Inc. (NYSEMKT:MSTX) which led to swings in the share price. The stock opened for trading at $0.142 and hit $0.148 on the upside , eventually ending the session at $0.1464, with a gain of 8.44% or 0.0114 points. The heightened volatility saw the trading volume jump to 9,550,168 shares. The 52-week high of the share price is $0.7088 and the company has a market cap of $37 million. The 52-week low of the share price is at $0.068 .

Company has reported several Insider transactions to the SEC, on Mar 30, 2015, Brandi Roberts (CFO) purchased 38,000 shares at 0.50 per share price.

Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The companys lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California.

Mast

Share this post

Leave a Reply